High-fidelity Cas13 variants with minimal collateral RNA targeting
A recent study published in Nature Biotechnology revealed the development of high-fidelity Cas13 variants with markedly reduced collateral effects by mutagenesis and demonstrated the feasibility of hfCas13 for efficient on-target ...